NBTF Introduces Neuroscience Nurse Consultations

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

OAKLAND, California-The National Brain Tumor Foundation (NBTF) has announced its new cancer online resource and toll-free telephone number. Patients and family members who have detailed medical questions regarding brain tumors can contact a neuroscience nurse for a free consultation.

OAKLAND, California—The National Brain Tumor Foundation (NBTF) has announced its new cancer online resource and toll-free telephone number. Patients and family members who have detailed medical questions regarding brain tumors can contact a neuroscience nurse for a free consultation.

“Our service is providing patients with the information to understand their treatment options,” said Mary Lovely, RN, PhD, of the NBTF. The neuroscience nurses are experienced interviewers with advanced knowledge of the diseases and a great deal of sensitivity to patient needs, she added.

The Patient Information Line, 1-800-934-CURE, provides current disease-related information on tumor types, treatment, and coping. Information specialists are available to speak with callers Monday through Friday from 9 am to 5 pm Pacific Standard Time.

Callers may also use the automated response system to order free materials on brain tumors and obtain information about the foundation and its programs or leave a recorded message. All messages are returned the next business day.

Instant access to the foundation’s resources is available on its website, located at www.braintumor.org.

The site also includes stories about other brain tumor survivors, a special pediatric page, and an illustrated guide to the brain.

Recent Videos
1 expert is featured in this series.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
4 experts are featured in this series.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Related Content